JCAR014: Phase I data

A Phase I trial showed that JCAR014 led to complete or partial remission in 6 of 10 evaluable patients with non-Hodgkin’s lymphoma (NHL) and 2 of 2 evaluable patients with chronic lymphocytic leukemia...